CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
[¹⁴C]-LY3337641drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02914379
NCT02914379Phase 1Completed
CompareCT.gov

Disposition of [¹⁴C]-LY3337641 Following Oral Administration in Healthy Male Subjects

Eli Lilly and Company·interventional·Posted Sep 26, 2016·Updated Aug 25, 2023

In Brief

A Phase 1 clinical trial evaluating [¹⁴C]-LY3337641 for Healthy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated. Participants will be admitted to a clinical research unit (CRU) the day before dosing. Participants remain confined to the CRU for at least 7 days. Participants may be discharged from the CRU any time after 7 days post-dose (Day 8), and up to a maximum of 21 days post-dose (Day 22). This study will last approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 26, 2016
Enrollment StartSep 1, 2016
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.8 years ago

Interventions

[¹⁴C]-LY3337641drug

Administered orally